Trump’s Taking Of Hydroxychloroquine May Be Tied To Family’s Stake In The Company That Makes It
President Trump revealed to the world earlier this week that he has been taking hydroxychloroquine, the antimalaria drug that the FDA has warned could cause heart problems. Trump says he is taking the medicine to ward off the coronavirus. It was confirmed on Wednesday that White House Doctor, Dr. Conely, did prescribe the potentially dangerous drug to President Trump. Now there is news that may reveal why Trump is promoting the drug.
It came to light on Monday that Trump has a financial interest in the company that makes hydroxychloroquine. The report was filed by The New York Times. Sanofi is the name of the French company that makes hydroxychloroquine better known by its brand name, Plaquenil. The Trump family has a small stake in Sanofi and they stand to make a nice financial gain should the drug become a standard treatment.
The New York Times found out about Trump’s ties to the company by looking at his 2019 Executive Branch Personnel Public Financial Disclosure Reports.
The money is coming from three family trusts tied to the Trump family which has funds anywhere from $1,001 and $15,000 invested in the Dodge & Cox International Stock Fund. this report is filed with the U.S. Office of Government Ethics. The NYT pointed out that the largest individual holding in the mutual fund is Sanofi. “At last check was 3.3%,” is what MarketWatch said of the size of the fund’s stake.
This will no doubt cause more speculation as to why the President is pushing a drug that could be very dangerous for America. It will be interesting to see what ethical considerations this might bring.